Referenceprogram for unipolar depression hos voksne

140. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD,
Wohlreich MM. Duloxetine versus escitalopram and placebo in the treatment of patients with major
depressive disorder: Onset of antidepressant action, a non-inferiority study. Curr Med Res Opin.
2007;23:401-416.
141. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S, Mirtazapine-Venlafaxine Study Group.
Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J
Clin Psychopharmacol. 2001;21:425-431.
142. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J
Clin Psychiatry. 2000;61:656-663.
143. Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: Efficacy and
tolerability in comparison with fluoxetine in patients with moderate to severe major depressive
disorder. mirtazapine-fluoxetine study group. J Clin Psychiatry. 1998;59:306-312.
144. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ. A double-blind, randomized, groupcomparative
study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine
in depressed chinese patients. J Clin Psychiatry. 2003;64:921-926.
145. Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M. A multicentre, double-blind,
clomipramine-controlled efficacy and safety study of org 3770. Hum Psychopharmacol. 1995;10:263-
271.
146. Bruijn JA, Moleman P, Mulder PG, van den Broek WW, van Hulst AM, van der Mast RC, van
de Wetering BJ. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in
depressed in-patients. Psychopharmacology (Berl). 1996;127:231-237.
147. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared
with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur
Neuropsychopharmacol. 1997;7 Suppl 1:S37-47; discussion S71-3.
148. Gallen C, Brown M. Reboxetine, placebo and paroxetine comparison in patients with
major depressive disorder: A double-blind, placebo- and comparator-controlled study. Eur
Neuropsychopharmacol. 2001;11:S216.
149. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline
selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin
Psychopharmacol. 2002;22:393-399.
150. Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of
antidepressant therapies: A prospective clinical practice study. J Clin Psychiatry. 2001;62:117-125.
151. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than
clomipramine in a controlled multicenter study. danish university antidepressant group. J Affect Disord.
1993;28:105-116.
152. Vejledning Om Behandling Med Antidepressiva ; Vejledning Om Behandling Med Antipsykotika ;
Vejledning Om Behandling Af Børn Med Antidepressiva, Antipsykotika Og Centralstimulerende Midler.
[Kbh.]: Sundhedsstyrelsen; 2000.
112
Referenceprogram for unipolar depression hos voksne